Outcomes Of Intralesional Bleomycin For The Management Of Cutaneous Low Flow Venous Malformations
European Journal of Molecular & Clinical Medicine,
2023, Volume 10, Issue 2, Pages 128-132
AbstractBackground: Venous malformations are a type of vascular malformation with abnormally developed vein, venules and venous capillaries bunching together to produce soft cystic reducible masses containing venous blood. They account for about two third of vascular malformations. It may involve skin, mucosa or any other part of the body. The aim of this study was to evaluate the efficacy and safety of intralesional bleomycin sclerotherapy in low flow venous malformations.
Materials and Methods: During 2019- 2022, 213 patients with cutaneous venous malformations were treated with bleomycin sclerotherapy at a tertiary care hospital. The diagnosis of venous malformation was made on the basis of clinical history and physical examination and confirmed by doppler ultrasonographic examination Only patients with low flow venous malformations were treated with intralesional bleomycin sclerotherapy.
Results: All were treated with intralesional bleomycin (0.1 I.U/ kg body weight) on an outpatient basis. Complete resolution (grade 4) was observed in 76(35.6%) patients and almost complete resolution (grade 3) with very minimal residual lesion or pigmentation was seen in 89(41.7%) patients thus producing a complete or near complete response in 77.3% patients.
Conclusion: Intralesional bleomycin sclerotherapy is an excellent treatment modality for the management of low flow venous malformations with very low procedural morbidity.
- Article View: 18
- PDF Download: 79